Business
Completion of Ovarian Cancer Pre-Study
Completion of Ovarian Cancer Pre-Study.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 1523B Angle PLC 05 June 2019 \n\n\n\n\n\n\n\nFor immediate release\n\n\n 5 June 2019\n \n\n\n\n\n\n\n\n\n\n\nANGLE plc (\"the Company\")\n \nSUCCESSFUL COMPLETION OF OVARIAN CANCER PRE-STUDY \n \nPre-study demonstrates ANGLE's optimised sample-to-answer molecular solution with patient samples\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that the first phase of its ovarian cancer clinical verification study (\"the pre-study\") has reported positive results. \n \nThe pre-study, undertaken by Dr. Richard Moore and colleagues at the University of Rochester Medical Center Wilmot Cancer Institute (Rochester), was designed to evaluate the use of ANGLE's modified and further optimised ParsortixTM and HyCEADTM Ziplex® platforms as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass, in a clinical setting and with clinical samples. \n \nThe pre-study comprised the evaluation of blood samples from 26 Stage III/IV ovarian cancer patients and 28 healthy volunteers using ANGLE's sample-to-answer molecular solution: Parsortix harvested circulating tumour cells and HyCEAD-Ziplex performed multiplex RNA expression analysis of those cells. The observed discrimination between cancer patients and healthy volunteers suggests the potential for both high sensitivity (correctly detecting cancer) and high specificity (correctly detecting no cancer i.e. low false positives). \n \nThe pre-study results demonstrate that the optimisation of the sample-to-answer molecular solution has been successful, paving the way to initiate the 200 subject ovarian cancer clinical verification study of patients who are presenting with a pelvic mass and scheduled for surgery. A positive outcome from the clinical verification study would support ANGLE's plans to launch a clinical assay for the detection of ovarian cancer in women with an abnormal pelvic mass.\n \nThis study is expected to start in early Q3 CY19 and is projected to complete in Q1 CY20. Project timelines assume a similar enrolment rate to the previous 200 patient pelvic mass study conducted by the same clinical centre but patient enrolment is outside of the Company's control. \n \n \nANGLE Founder and Chie...